Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 6 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

535 BC3195, a novel cadherin-3 targeting antibody drug conjugate, combined with pembrolizumab in patients with advanced solid malignancies: preliminary results from a phase I/II study (BC3195-103/G36)

  • Yi-Long Wu1
  • Hai-jun Guo2
  • Chongrui Xu3
  • Fa-Man Xiao4
  • Ji-Lin Guan4
  • Yue-Li Sun4
  • Xiang-Yun Ye5
  • Yi-Wei Wang5
5 affiliations
  1. 11 Guangdong Lung Cancer Institute, Guangdong Provincial People`s Hospital, Guangzhou, Guangdong, China
  2. 2Center for Environment and Population Health, Griffith University, Nathan, Queensland, Australia
  3. 3Guangdong Provincial People’s Hospital, Guangzhou, Guangdong, China
  4. 4Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China
  5. 5Biocity Biopharmaceutics Co. Ltd, Shanghai, China
Open at sourcePDFDOICite

Related

  1. Domain-resolved epitope mapping of B7-H3-targeting VHH-Fcs defines isoform-selective binders for antibody-drug conjugate development
    X. Fang, B. Chalopin, S. S. Gokturk +14
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
  2. Targeting CD28 on T lineage malignancies with chimeric antigen receptor T cells
    Semjon Willier, Julian Färber, Theodora Ispyrlidou +22
    Nature CommunicationsPeer-reviewedCC BY 4.0Full textOncologyCrossref
  3. Targeting tumor-selective membrane-associated PCNA enables selective antibody-drug conjugate therapy.
    Muhammad Abu Ahmad, Nir Miriam Ungar-Malma, Alon Naumchik +11
    OncoimmunologyPeer-reviewedCC BY-NCFull textMedical imaging & radiologyEurope PMC
  4. Quantitative Systems Pharmacology Model for Trop-2 Targeting Antibody-Drug Conjugate in Triple-Negative Breast Cancer
    S. Dogru, A. Suresh, E. P. Bowman +3
    bioRxivPreprintCC BY-NC-NDFull textPharmacology & toxicologybioRxiv
  5. Antibody-drug conjugate combination therapy targeting LGR5 and MET with different payloads enhances efficacy in preclinical colorectal cancer models
    S. Subramanian, P. C. High, C. Guernsey-Biddle +7
    bioRxivPreprintCC BY-NDFull textOncologybioRxiv

Cite

BibTeXRIS
BibTeX
@article{wu2026bc3195,
  title = {{535 BC3195, a novel cadherin-3 targeting antibody drug conjugate, combined with pembrolizumab in patients with advanced solid malignancies: preliminary results from a phase I/II study (BC3195-103/G36)}},
  author = {Yi-Long Wu and Hai-jun Guo and Chongrui Xu and Fa-Man Xiao and Ji-Lin Guan and Yue-Li Sun and Xiang-Yun Ye and Yi-Wei Wang},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0535},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0535},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 535 BC3195, a novel cadherin-3 targeting antibody drug conjugate, combined with pembrolizumab in patients with advanced solid malignancies: preliminary results from a phase I/II study (BC3195-103/G36)
AU  - Yi-Long Wu
AU  - Hai-jun Guo
AU  - Chongrui Xu
AU  - Fa-Man Xiao
AU  - Ji-Lin Guan
AU  - Yue-Li Sun
AU  - Xiang-Yun Ye
AU  - Yi-Wei Wang
PY  - 2026
DA  - 2026/11/06
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0535
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0535
SN  - 2051-1426
ER  -